Client
The World
Key Areas
Science storytelling
Science writing
Information design
Site development

COVID-19 & SARS-CoV-2

First published Feb. 13, 2020.
Last updated Nov. 17, 2020, @ 9 am PT.

Background

The novel coronavirus, SARS-CoV-2, is the cause of COVID-19, a severe acute respiratory disease first detected in Wuhan, China. The spread of COVID-19 is a global health risk that has had a significant impact on the economy and daily lives of people across the globe.

 
 
 

Many therapies with diverse mechanisms of action are currently being tested as treatments for COVID-19 and the antiretroviral medication prodrug remdesivir has been FDA approved. Click the “view the poster” link below to see an 18″ x 24″ downloadable poster presenting information about the SARS-CoV-2 RNA-dependent RNA Polymerase (RdRp) and Remdesivir Mechanism of Action.

View the poster!

 
The poster is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License. See poster footer for license and attribution.
 
 
Signs & Symptoms

The Centers for Disease Control & Prevention (CDC) believes at this time that symptoms of COVID-19 may appear in as few as two days or as long as 14 after exposure. Individuals with symptoms including, fever, coughing, and shortness of breath should self-isolate and seek COIVD-19 diagnostic and medical advice.1,7 The clinical spectrum of COVID-19 ranges from mild, cold-like symptoms to severe pneumonia, respiratory failure, and in some cases, death.7

 
Anyone can be infected by the virus that causes COVID-19, but certain populations appear to be more vulnerable to severe infection: recent evidence suggests that older individuals and those with underlying medical conditions are more likely to experience complications or hospitalization.7
 
 
Spread of Infection

The WHO has designated the outbreak a global health emergency.3 As of Nov. 17, 2020, there have been 55,204,949 confirmed COVID-19 cases (up 4,654,887 from Nov. 9). Of the total cases, 35,490,309 individuals have recovered, and 1,330,299 have died (up 71,978 from Nov. 9), of which 247,356 are from the U.S. (up 9,737 from Nov. 9).

The case fatality ratio (CFR), measures the proportion of deaths among identified confirmed cases. The relative risk of mortality for different groups of people and countries helps guide resource allocation and policy decisions. The level of transmission in a population may be underestimated if individuals with mild or no symptoms are missing from the data or if under-served groups have decreased access to health care or testing.4

spread of Infection: U.S. Status Report

COVID-19 cases have been reported in all 50 states, with more than 10,000 cases reported in almost every state. Despite these guidelines, COVID-19 cases are surging throughout the southern and western United States. Despite social distancing guidelines and orders to wear masks in public places to prevent community spread, COVID-19 cases are surging across the United States. Many states, particularly in the Midwest, are reporting record numbers of daily cases.

 
On March 11, the WHO Director-General announced that COVID-19 can be characterized as a pandemic.   On February 28, the WHO raised the Global Risk Assessment level for COVID-19 from high to very high.2   Person-to-person spread (or community spread) has occurred in China and now also appears to be happening in countries all over the world.7
 
 
Anatomy of SARS-CoV-2

From the beginning of the COVID-19 outbreak, the combination of many expedited studies has revealed an unprecedented amount of information for a new disease, including the causative virus (SARS-CoV-2), its genetic sequence, PCR assays, and serological analyses. Efforts are rapidly ongoing with the aim of quickly designing effective treatments, such as a vaccine or antiviral drug.

 
 
 
SARS-CoV-2 Mechanism of Action

Once in the body, SARS-CoV-2 recognizes and attaches to a transmembrane protein called ACE2 found mainly on cells that line our airways. The effectiveness of SARS-CoV-2 in triggering respiratory disease may be due to the evolved structure of the Spike (S) protein, which contains the receptor-binding domain for ACE2 and creates the virus’s recognizable ‘crown’ shape. After binding to an ACE2 homodimer, the virus enters the cell through a process called receptor-mediated endocytosis. Inside the cell, the virus releases its RNA and takes advantage of the host cell’s machinery, allowing it to reproduce, escape, and continue infecting human tissue.

 
 
 
Situation in Numbers:
How COVID-19 Compares to Other Outbreaks

As more cases emerge, medical professionals and researchers have been able to identify distinguishing traits of COVID-19. Here is a look at other notable viral diseases to show how COVID-19 compares.

 
 
 
References
  1. Coronavirus Disease 2019 (COVID-19) – Symptoms. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Published April 27, 2020. Accessed April 28, 2020.
  2. World Health Organization (2020). Novel Coronavirus (2019-NCoV) Situation Reports. who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
  3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020.
    doi:10.1016/s0140-6736(20)30211-7.
  4. “The Urgent Questions Scientists Are Asking About Coronavirus.” The New York Times, 10 Feb. 2020, https://www.nytimes.com/2020/02/10/opinion/coronavirus-china-research.html
  5. Branswell H. The Coronavirus Questions That Scientists Are Racing to Answer. Scientific American. https://www.scientificamerican.com/article/the-coronavirus-questions-that-scientists-are-racing-to-an swer/. Published January 28, 2020.
  6. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv (preprint). 2020. doi:10.1101/2020.01.26.919985
  7. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html. Published January 10, 2020. Accessed March 13, 2020.
  8. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the International Journal of Infectious Diseases. 2020. doi:10.1101/2020.01.23.916395
  9. @DrewQJoseph AJ, Joseph A, Joseph A, et al. First case of coronavirus spread by a person showing no STAT.
  10. “Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS).” World Health Organization, World Health Organization, 23 July 2015, who.int/csr/sars/country/en/.
  11. “Middle East respiratory syndrome.” World Health Organization, World Health Organization, emro.who.int/health-topics/mers-cov/mers-outbreaks.html.
  12. Factsheet about Middle East respiratory syndrome coronavirus (MERS-CoV). European Centre for Disease Prevention and Control.
    https://www.ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus/factsheet.  Published February 10, 2020. Accessed February 11, 2020.
  13. Types of Influenza Viruses. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/about/viruses/types.htm. Published November 18, Accessed February 11, 2020.
  14. “Weekly U.S. Influenza Surveillance Report.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 7 Feb. 2020, www.cdc.gov/flu/weekly/index.htm
  15. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infectious Diseases. 2014;14(1). doi:10.1186/1471-2334-14-480
  16. Transmission of Avian Influenza A Viruses Between Animals and People. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/avianflu/virus-transmission.htm. Published February 10, 2015. Accessed February 11, 2020.
  17. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014;14(1):480. doi:10.1186/1471-2334-14-480
  18. Fraser C, Cummings DAT, Klinkenberg D, Burke DS, Ferguson NM. Influenza Transmission in Households During the 1918 Pandemic. Am J Epidemiol. 2011;174(5):505-514. doi:10.1093/aje/kwr122
  19. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis. 2007;195(7):1018-1028. doi:10.1086/511989
  20. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300. doi:10.1016/S1473-3099(09)70069-6
  21. Taubenberger JK, Baltimore D, Doherty PC, et al. Reconstruction of the 1918 Influenza Virus: Unexpected Rewards from the Past. mBio. 2012;3(5). doi:10.1128/mBio.00201-12
  22. 1918 Pandemic (H1N1 virus). https://www.cdc.gov/flu/pandemic-resources/1918-pandemic-h1n1.html. Published March 20, 2019. Accessed March 16, 2020.
  23. History of 1918 flu pandemic. https://www.cdc.gov/flu/pandemic-resources/1918-commemoration/1918-pandemic-history.htm. Published March 21, 2018. Accessed March 16, 2020.

The contents of this Case Study, including scientific visualizations, tables, and visual plots, are © 2020 Cognition Studio Inc, all rights reserved. The content of this Case Study is provided to the public strictly for educational purposes. The Case Study relies on publicly available data from multiple sources that do not always agree. As a result of this, Cognition Studio disclaims any representations and warranties concerning the Case Study’s accuracy. Reliance on the Case Study for medical guidance or use of the Case Study for commercial use is strictly prohibited.

 

More Work.

education
Educating about phthalates and bisphenol A
brand
Healthcare delivered at the fingertips of consumers
science storytelling
Blockbuster small molecule set to rival Ibrutinib